ScripEli Lilly’s blockbuster obesity and type 2 diabetes therapy, Mounjaro (tirzepatide) has made its India debut throwing down the gauntlet to rival Novo Nordisk, currently in the wings with Wegovy (injec
ScripNovo Nordisk is to pay $200m upfront to in-license a ‘triple G’ agonist obesity candidate, helping it compete head-to-head with fierce rival Eli Lilly. The deal with China-based United Bio-Technology
In VivoIn biotechnology, funding remains the critical catalyst that transforms scientific discoveries into life-changing therapies. At the recent BioEurope conference in Milan, Laura Lane, head of Europe for
ScripArmed with an impressive series A financing that has raked in €77.7m ($84.8m), Augustine Therapeutics has ambitions to be a leading player in the histone deacetylase 6 (HDAC6) inhibition space for the